Metabolism open · 2025
First European case of Geller syndrome complicated with hypokalemic nephropathy: A case report and literature review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gavriilidis Efstratios, Antoniadou Christina, Dimopoulou Georgia, Papadimitriou Evangelos, Bakola Stefania-Aspasia, Papagoras Charalampos, Skendros Panagiotis, Tsilingiris Dimitrios
Аннотация
Geller syndrome is caused by a gain-of-function mutation in the mineralocorticoid receptor (MR), rendering it prone to activation by elevated progesterone levels during pregnancy. It is characterized by gestational hypertension and hypokalemia. We describe the case of a 35-year-old primigravida, who presented at 22 weeks of gestation with severe hypokalemia and hypertension, complicated by hypokalemic nephropathy manifesting as diabetes insipidus and proteinuria. Initial potassium replacement, eplerenone administration and desmopressin were insufficient, whereas the administration of amiloride, a potassium-sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal nephron, led to complete resolution of the clinical syndrome. The patient had no further complications and delivered a healthy infant at 37 weeks. Genetic testing did not reveal known MR mutations, suggesting that other genetic variants or epigenetic changes in MR may warrant future investigation, particularly in isolated populations. To date, 17 cases of Geller syndrome have been reported in the literature including the herein presented, which is to the best of our knowledge the first documented in Europe. Genetic testing was performed in only one case, apart from the initially reported ones. Urgent delivery was required in four cases, while amiloride, the treatment of choice, was administered in only five, highlighting the importance of early recognition of the syndrome for effective management and prevention of adverse pregnancy outcomes.